O

SEC EDGAR - Form 4 insider activity

Oramed Pharmaceuticals Inc. $ORMP

Tracked equity - 6 filings indexed by Nortis

Nortis signal thesis

Cluster activity detected. Review whether the filings are open-market trades or routine compensation events.

0

OM buys - 90d

2

OM sells - 90d

4

Routine filings

4

Cluster filings

$135.3K

Largest trade

28/100

Avg signal score

Filing tape

Recent filings

Last 30d: 6
Open-market SellNotable 50/100
filed 2026-10-02
GACFO

Gabay Avraham - Chief Financial Officer - $90.2K

Insiders sell for many reasons (diversification, tax, personal); size and clustering matter more than a single sale.

View source filing
Open-market SellNotable 56/100
filed 2026-10-02
HJInsider

Hexter Joshua - COO & CBO - $135.3K

Insiders sell for many reasons (diversification, tax, personal); size and clustering matter more than a single sale.

View source filing
Grant / AwardCLUSTERRoutine 15/100
filed 2026-09-25
KNCEO

KIDRON NADAV - Director, President and CEO

This is compensation-related stock, not a purchase decision - it should not be read as an open-market buy. It is part of a cluster (3+ insiders within 7 days), which is generally more notable than an isolated filing.

View source filing
Grant / AwardCLUSTERRoutine 15/100
filed 2026-09-25
HJInsider

Hexter Joshua - COO & CBO

This is compensation-related stock, not a purchase decision - it should not be read as an open-market buy. It is part of a cluster (3+ insiders within 7 days), which is generally more notable than an isolated filing.

View source filing
Grant / AwardCLUSTERRoutine 15/100
filed 2026-09-25
KMBoard

Kidron Miriam - Director, Chief Scientific Officer

This is compensation-related stock, not a purchase decision - it should not be read as an open-market buy. It is part of a cluster (3+ insiders within 7 days), which is generally more notable than an isolated filing.

View source filing
Grant / AwardCLUSTERRoutine 15/100
filed 2026-09-25
GACFO

Gabay Avraham - Chief Financial Officer

This is compensation-related stock, not a purchase decision - it should not be read as an open-market buy. It is part of a cluster (3+ insiders within 7 days), which is generally more notable than an isolated filing.

View source filing